TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
0.5674
-0.0282 (-4.73%)
At close: Apr 10, 2026, 4:00 PM EDT
0.5660
-0.0014 (-0.25%)
After-hours: Apr 10, 2026, 4:04 PM EDT
TELA Bio Revenue
In the year 2025, TELA Bio had annual revenue of $80.28M with 15.84% growth. TELA Bio had revenue of $20.87M in the quarter ending December 31, 2025, with 18.24% growth.
Revenue (ttm)
$80.28M
Revenue Growth
+15.84%
P/S Ratio
0.32
Revenue / Employee
$384,091
Employees
209
Market Cap
25.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 80.28M | 10.98M | 15.84% |
| Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
| Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
| Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
| Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
| Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
| Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
| Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
| Dec 31, 2017 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Nortech Systems | 118.37M |
| Myomo | 40.93M |
| Cytosorbents | 37.06M |
| Lifeward | 22.03M |
| Pulsenmore | 12.55M |
| NeuroOne Medical Technologies | 11.72M |
| IceCure Medical | 3.38M |
TELA News
- 16 days ago - TELA Bio Analysts Cut Their Forecasts After Q4 Results - Benzinga
- 17 days ago - TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings - Benzinga
- 5 months ago - TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 months ago - TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility - GlobeNewsWire